For research and education only · Not reviewed by a medical professional · Disclaimer

← PepsRadar home

EXPLORE THE BIOLOGY

Peptides for Inflammation & Immunity: What the Human Evidence Shows

Content updated · how dates work

Host defense, immune signaling, and inflammation.

This topic groups related research questions. Shared biology does not make different peptides interchangeable, or establish a clinical benefit. Compare each paper’s population, preparation, and measured outcome.

Immune & inflammation: what the human evidence shows

Each peptide is sorted by the strongest kind of human study among its profile’s selected studies, and the row shows what that study found and who was studied. A higher tier means stronger evidence exists, not that the peptide works for immune & inflammation: the best trial may be small, negative or about a different condition. No doses.

PeptideStrongest human evidence in our sourcesFDAHuman safety data
Randomized human trials (5)At least one randomized or placebo-controlled trial, which may be small, negative or about another condition.
ARA-290Sarcoidosis-associated small-fiber neuropathy pilot (2012) · Human randomized pilot trial
The small-fiber-neuropathy symptom score improved more with ARA-290. Brief Pain Inventory pain and fatigue measures improved similarly in both groups; depression did not change.
Limitation: A small, short pilot cannot establish durable recovery. A positive neuropathy score should not be presented as a significant benefit on every measured pain or fatigue outcome.
Studied: 22 people with sarcoidosis and small-fiber neuropathy.
Not approvedTrials only
EnfuvirtideTORO-1 (2003) · Human randomized trial
Viral load fell by 1.696 versus 0.764 log10 copies per milliliter. CD4 counts increased by 76 versus 32 cells per cubic millimeter.
Limitation: The treatment was added to an optimized regimen, so its use is not equivalent to monotherapy. Short-term viral and cell-count outcomes are distinct from long-term clinical outcomes.
Studied: 501 people with HIV and substantial prior antiretroviral treatment or resistance.
WithdrawnFDA label
LL-37LL-37 · first topical ulcer trial (2014) · Human randomized trial
The lowest concentration had a significantly higher healing-rate constant than placebo (P=0.003); the middle comparison did not reach significance (P=0.088). The highest concentration showed no healing difference.
Limitation: Small sample and short follow-up limit confidence. The later 148-person trial did not improve healing overall. These topical findings do not establish systemic antimicrobial efficacy or safe injectable use.
Studied: 34 people with hard-to-heal venous leg ulcers.
Not approvedTrials only
ThymopentinThymopentin rheumatoid-arthritis study (1985) · Human randomized trial
Some joint, pain, and Ritchie-index measures improved between groups. The reported immunological tests did not show corresponding improvements.
Limitation: The trial was small, short, and historical. It does not establish sustained disease control, prevention of structural joint damage, or benefit across unrelated immune conditions.
Studied: 41 patients with active rheumatoid arthritis; 21 received thymopentin and 20 received placebo.
Not approvedTrials only
VIPTESICO aviptadil trial (2023) · Human randomized trial
The primary outcome was not significantly better with aviptadil: odds ratio 1.11, 95% CI 0.80–1.55, P=0.54. Mortality was also not significantly different.
Limitation: This negative comparison should remain visible. It neither proves benefit nor answers every proposed chronic use of VIP.
Studied: 461 people with COVID-19-associated respiratory failure.
Not approvedTrials only
Small or uncontrolled human studies (3)Human reports without randomization, such as pilots, case series or open-label studies.
ThymalinThymalin and Epithalamin in older adults (2003) · Human clinical report with limited abstract methods
The authors reported lower illness and mortality measures in treated groups.
Limitation: Limited accessible methods and multiple preparations prevent a strong causal interpretation. Reported associations should not be presented as proof of lifespan extension.
Studied: 266 elderly participants in a reported six-to-eight-year follow-up.
Not approvedVery limited
Thymosin alpha-1TESTS (2025) · Human phase 3 trial
Twenty-eight-day mortality was 23.4% versus 24.1%; hazard ratio 0.99 (95% CI 0.77–1.27). No clear mortality benefit was demonstrated.
Limitation: A large negative overall result should not be replaced by favorable subgroup headlines. Sepsis treatment also differs substantially from immune-enhancement claims in healthy people.
Studied: 1,106 adults with sepsis randomized across 22 centers in China.
Not approvedVery limited
ThymulinZinc status and thymulin activity (1988) · Human physiological study
Thymulin activity was lower in zinc-deficient settings and was restored with zinc in the reported in-vivo and in-vitro experiments.
Limitation: These findings do not establish clinical benefit from injecting thymulin or treating people who are not zinc deficient.
Studied: 14 participants across experimentally induced zinc deficiency, sickle-cell anemia, and other clinical groups.
Not approvedNone
Animal and lab studies only (3)No human study in our sources.
CortistatinSee the profile for the animal and lab research.Not approvedNone
KPVSee the profile for the animal and lab research.Not approvedNone
Peptide bioregulators (Khavinson peptides)See the profile for the animal and lab research.Not approvedVery limited

Selected studies, not a systematic review. Approval belongs to a specific product and use. Side-by-side comparisons: Thymosin alpha-1 vs Thymosin beta-4 (all comparisons).

ARA-290

ARA-290, also called cibinetide, is an erythropoietin-derived peptide investigated in tissue-protection research. A small clinical pilot examined neuropathy symptoms in people with sarcoidosis.

Research topics

Read the studies →

Cortistatin

Cortistatin is a neuropeptide family investigated in inflammatory signaling. The selected study used a mouse arthritis model rather than people with rheumatoid arthritis.

Research topics

Read the studies →

Enfuvirtide

Enfuvirtide is an HIV fusion inhibitor with historical combination-treatment evidence. MedlinePlus reports that the injection has been discontinued in the United States.

Clinical medicines

Read the studies →

KPV

KPV is a three-amino-acid peptide investigated in intestinal and immune-cell research. Its short sequence does not make clinical efficacy self-evident.

Research topics

Read the studies →

LL-37

LL-37 is the only human cathelicidin: a 37-amino-acid host-defense peptide made by white blood cells and by the lining of the skin, gut and airways. As a treatment it has been tested only on the skin of chronic ulcers. A small 2014 trial was positive, but a 148-patient phase 2b trial missed its main healing goal.

Research topics

Read the studies →

Peptide bioregulators (Khavinson peptides)

Peptide bioregulators are very short synthetic peptides, two to four amino acids long, developed by Vladimir Khavinson and colleagues in St. Petersburg. Each is named for the tissue it was proposed to support. Almost all published research on them comes from that group and its collaborators.

Research topics

Read the studies →

Thymalin

Thymalin is a thymus-derived extract or peptide mixture. An older clinical report described long-term outcomes in elderly participants, but the abstract does not establish the methods needed for a firm causal longevity claim.

Research topics

Read the studies →

Thymopentin

Thymopentin is a synthetic pentapeptide studied as an immunomodulator. A small 1985 randomized trial examined active rheumatoid arthritis.

Research topics

Read the studies →

Thymosin alpha-1

Thymosin alpha-1, also called thymalfasin, is investigated for immune-related effects. The clinical value of immune modulation depends on the disease and endpoint.

Research topics

Read the studies →

Thymulin

Thymulin is a thymic peptide whose biological activity depends on zinc. The featured human study examined zinc status and thymulin activity; it was not a trial of thymulin injections.

Research topics

Read the studies →

VIP

Vasoactive intestinal peptide participates in vascular and immune signaling. A large trial of intravenous aviptadil in COVID-19 respiratory failure did not show a significant improvement in its primary outcome.

Research topics

Read the studies →

See something wrong on this page? Report a mistake · Corrections

FREE PEPSRADAR ACCOUNT

We check sellers’ lab reports with the testing labs themselves.

So far 89 of the 105 lab reports we looked up matched the testing lab’s own record, and 12 did not.

A free account shows which sellers, report by report, plus daily prices, deals, Ask PepsRadar and alerts. If you want it, the PepsRadar Weekly brings new research and FDA news once a week. No dosing advice.

Create a free accountWhat members get →